{"id":2590,"date":"2018-03-15T20:45:08","date_gmt":"2018-03-15T15:15:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2590"},"modified":"2021-07-24T12:56:58","modified_gmt":"2021-07-24T07:26:58","slug":"business-cocktail-biogen-news-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>M&amp;A activity of <a href=\"https:\/\/www.sanofi.com\/\">Sanofi<\/a> and Bioverative for rare blood diseases<\/strong><\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.sanofi.com\/\">Sanofi<\/a> has strengthened its position in hematology &amp; speciality medicine by acquiring Bioverativ, Biogen hemophilia &amp; blood disorders-focused company for USD 105 per share on March 8, 2018. This will increase Sanofi\u2019s hemophilia portfolio for the treatment of hemophilia A and hemophilia B.<\/p>\n<p style=\"text-align: justify;\"><strong>Netherlands biotech Escalier gets\u00a0USD 19 Million for pivotal dermatology\u00a0assessments<\/strong><\/p>\n<p style=\"text-align: justify;\">New Science Ventures, BioGeneration Ventures and European VC firm Forbion to raise USD 19 million for the development of drugs for Escalier Biosciences. This financial partnership will develop the treatment for dermatologic, psoriasis and other autoimmune diseases.<\/p>\n<p style=\"text-align: justify;\"><strong>Crinetics bags USD 63.5 Million for acromegaly treatment <\/strong><\/p>\n<p style=\"text-align: justify;\">Crinetics successfully bagged USD 63.5 million in the second round of funding to take its oral drug candidate to the injectable platform for acromegaly. The fundraising will help in further development of CRN00808. This will be more favorable to the patient to get alternative of CRN00808 for the existing drugs like Novartis\u2019 Signifor (pasireotide) and Pfizer\u2019s Somavert (pegvisomant).<\/p>\n<p style=\"text-align: justify;\"><strong>Another Failure of Auris\u2019 Tinnitus Drug in Phase 3<\/strong><\/p>\n<p style=\"text-align: justify;\">After its failure in 2016 Auris had made improvements for its second study. Changes were made in the primary endpoint &amp; added a subgroup analysis still the trail failed. The failure of trails on tinnitus scale, AM-111 &amp; otitis media subgroup has put Auris in penny-stock territory. However, Auris is discussing the path forward for AM-111 with regulatory affairs.<\/p>\n<p style=\"text-align: justify;\"><strong>Biogen pays USD 75 Million for Pfizer\u2019s schizophrenia drug <\/strong><\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.biogen.com\/en_us\/home.html\">Biogen<\/a> has purchased Pfizer\u2019s phase 2-ready PF-04958242, a schizophrenia drug. It will invest USD 75 million for the upfront of the therapy while USD 515 million &amp; tiered royalties will come into picture only if it gets approved.<\/p>\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>M&amp;A activity of Sanofi and Bioverative for rare blood diseases Sanofi has strengthened its position in hematology &amp; speciality medicine by acquiring Bioverativ, Biogen hemophilia &amp; blood disorders-focused company for USD 105 per share on March 8, 2018. This will increase Sanofi\u2019s hemophilia portfolio for the treatment of hemophilia A and hemophilia B. Netherlands biotech [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1518,830,1514,776,1118,1155,1516,204,210,1515,460,1230,1261,1513,533,1519,1517],"industry":[17225],"therapeutic_areas":[17237,17278,17234],"class_list":["post-2590","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-auris","tag-biogen","tag-bioverative","tag-business-cocktail","tag-business-research","tag-consultancy","tag-crinetics","tag-delveinsight","tag-dermatology","tag-escalier","tag-pfizer","tag-pharma-consultancy","tag-pharma-consulting","tag-rare-blood-diseases","tag-sanofi","tag-schizophrenia","tag-tinnitus","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-other-diseases","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Business Cocktail (BIOGEN) - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"New Science Ventures, BioGen Ventures and European VC firm Forbion to raise USD 19 million for the development of drugs for Escalier Biosciences.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Business Cocktail (BIOGEN) - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"New Science Ventures, BioGen Ventures and European VC firm Forbion to raise USD 19 million for the development of drugs for Escalier Biosciences.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-15T15:15:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2450\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Business Cocktail (BIOGEN) - DelveInsight Business Research","description":"New Science Ventures, BioGen Ventures and European VC firm Forbion to raise USD 19 million for the development of drugs for Escalier Biosciences.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2","og_locale":"en_US","og_type":"article","og_title":"Business Cocktail (BIOGEN) - DelveInsight Business Research","og_description":"New Science Ventures, BioGen Ventures and European VC firm Forbion to raise USD 19 million for the development of drugs for Escalier Biosciences.","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-03-15T15:15:08+00:00","article_modified_time":"2021-07-24T07:26:58+00:00","og_image":[{"width":2450,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2","name":"Business Cocktail (BIOGEN) - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","datePublished":"2018-03-15T15:15:08+00:00","dateModified":"2021-07-24T07:26:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"New Science Ventures, BioGen Ventures and European VC firm Forbion to raise USD 19 million for the development of drugs for Escalier Biosciences.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-biogen-news-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","width":2450,"height":1080,"caption":"News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Auris<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bioverative<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Crinetics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dermatology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Escalier<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rare blood diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tinnitus<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Auris<\/span>","<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">Bioverative<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">Crinetics<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Dermatology<\/span>","<span class=\"advgb-post-tax-term\">Escalier<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">rare blood diseases<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia<\/span>","<span class=\"advgb-post-tax-term\">Tinnitus<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 15, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 15, 2018 8:45 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2590"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2590\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2434"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2590"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2590"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}